JP2006249089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006249089A5 JP2006249089A5 JP2006065731A JP2006065731A JP2006249089A5 JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5 JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006065731 A JP2006065731 A JP 2006065731A JP 2006249089 A5 JP2006249089 A5 JP 2006249089A5
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- imidazo
- pyridin
- carbonyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridin-1-yl Chemical group 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66059205P | 2005-03-11 | 2005-03-11 | |
| US60/660,592 | 2005-03-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006249089A JP2006249089A (ja) | 2006-09-21 |
| JP2006249089A5 true JP2006249089A5 (https=) | 2009-04-16 |
| JP5069415B2 JP5069415B2 (ja) | 2012-11-07 |
Family
ID=36649530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006065731A Expired - Lifetime JP5069415B2 (ja) | 2005-03-11 | 2006-03-10 | 結晶形態のイミダゾール誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7960407B2 (https=) |
| EP (1) | EP1861400B1 (https=) |
| JP (1) | JP5069415B2 (https=) |
| KR (1) | KR100911073B1 (https=) |
| CN (1) | CN101137656B (https=) |
| AR (1) | AR055567A1 (https=) |
| AT (1) | ATE469150T1 (https=) |
| AU (1) | AU2006221699A1 (https=) |
| BE (1) | BE2018C028I2 (https=) |
| BR (1) | BRPI0608819B8 (https=) |
| CA (1) | CA2600510C (https=) |
| DE (1) | DE602006014516D1 (https=) |
| ES (1) | ES2344310T3 (https=) |
| FR (1) | FR18C1028I2 (https=) |
| IL (1) | IL185145A0 (https=) |
| IN (1) | IN2014DN09939A (https=) |
| MX (1) | MX2007011110A (https=) |
| NL (1) | NL300944I2 (https=) |
| PL (1) | PL1861400T3 (https=) |
| RU (1) | RU2357968C1 (https=) |
| TW (1) | TW200643021A (https=) |
| WO (1) | WO2006095268A1 (https=) |
| ZA (1) | ZA200707568B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010034110A1 (en) * | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| EP2965756B1 (en) * | 2009-04-22 | 2018-10-10 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| US9457084B2 (en) | 2010-02-22 | 2016-10-04 | Raqualia Pharma Inc. | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases |
| RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
| RU2464042C1 (ru) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| CA2907049C (en) | 2013-03-19 | 2021-08-10 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
| CN107759590A (zh) * | 2014-03-06 | 2018-03-06 | 阿莱塔纳治疗学股份有限公司 | Grapiprant的结晶形式 |
| PT3113774T (pt) | 2014-03-06 | 2022-02-28 | Elanco Animal Health Incorporated | Composições de grapiprant e métodos de utilização das mesmas |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| US20210300921A1 (en) * | 2018-07-11 | 2021-09-30 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2021009251A (es) | 2019-01-30 | 2021-09-21 | Avista Pharma Solutions Inc | Proceso de sintesis y nuevos compuestos intermedios. |
| CA3128024A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| CA3223173A1 (en) | 2021-07-30 | 2023-02-02 | Raqualia Pharma Inc. | Crystalline forms |
| CN116478155B (zh) * | 2022-01-17 | 2025-06-13 | 洛阳惠中兽药有限公司 | 一种格拉匹伦及其中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| CN100579518C (zh) * | 2002-04-12 | 2010-01-13 | 美国辉瑞有限公司 | Ep4受体配体在制备治疗il-6相关疾病的药物中的应用 |
-
2006
- 2006-03-01 CA CA2600510A patent/CA2600510C/en not_active Expired - Lifetime
- 2006-03-01 AU AU2006221699A patent/AU2006221699A1/en not_active Abandoned
- 2006-03-01 AT AT06710609T patent/ATE469150T1/de not_active IP Right Cessation
- 2006-03-01 ES ES06710609T patent/ES2344310T3/es not_active Expired - Lifetime
- 2006-03-01 EP EP06710609A patent/EP1861400B1/en not_active Expired - Lifetime
- 2006-03-01 WO PCT/IB2006/000754 patent/WO2006095268A1/en not_active Ceased
- 2006-03-01 CN CN2006800079642A patent/CN101137656B/zh not_active Expired - Lifetime
- 2006-03-01 US US11/908,163 patent/US7960407B2/en active Active
- 2006-03-01 RU RU2007133802/04A patent/RU2357968C1/ru active
- 2006-03-01 MX MX2007011110A patent/MX2007011110A/es active IP Right Grant
- 2006-03-01 BR BRPI0608819A patent/BRPI0608819B8/pt active IP Right Grant
- 2006-03-01 DE DE602006014516T patent/DE602006014516D1/de not_active Expired - Lifetime
- 2006-03-01 KR KR1020077020701A patent/KR100911073B1/ko not_active Expired - Lifetime
- 2006-03-01 PL PL06710609T patent/PL1861400T3/pl unknown
- 2006-03-01 IN IN9939DEN2014 patent/IN2014DN09939A/en unknown
- 2006-03-09 TW TW095108018A patent/TW200643021A/zh unknown
- 2006-03-09 AR ARP060100886A patent/AR055567A1/es unknown
- 2006-03-10 JP JP2006065731A patent/JP5069415B2/ja not_active Expired - Lifetime
-
2007
- 2007-08-09 IL IL185145A patent/IL185145A0/en unknown
- 2007-09-03 ZA ZA200707568A patent/ZA200707568B/xx unknown
-
2018
- 2018-07-03 FR FR18C1028C patent/FR18C1028I2/fr active Active
- 2018-07-05 BE BE2018C028C patent/BE2018C028I2/nl unknown
- 2018-07-05 NL NL300944C patent/NL300944I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006249089A5 (https=) | ||
| CA2600510A1 (en) | Crystal forms of an imidazole derivative | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| RU2008143362A (ru) | Сокристаллическая форма производного с-гликозида c l-пролином | |
| RU2009122241A (ru) | Твердые формы рацемического илапразола | |
| JP2010514806A5 (https=) | ||
| ME02275B (me) | Polimorfni oblik rotigotina | |
| JP2009536176A5 (https=) | ||
| RU2598606C3 (ru) | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она | |
| JP2019503365A5 (https=) | ||
| JP2011522816A5 (https=) | ||
| JP2011528658A5 (https=) | ||
| JP2010514807A5 (https=) | ||
| JP2012533565A5 (https=) | ||
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| JP2011527333A5 (https=) | ||
| JP2016503010A5 (https=) | ||
| JP2012502037A5 (https=) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2023175694A5 (https=) | ||
| RU2009133262A (ru) | Нападизилатная соль антагониста мускаринового мз-рецептора | |
| HRP20171511T1 (hr) | Ivabradin-hidroklorid, oblik iv | |
| JP2021073257A5 (https=) | ||
| JP2020536893A5 (https=) | ||
| JP2009537554A5 (https=) |